DNA methylation and breast cancer: A way forward (Review)
- Authors:
- Maria Teresa Vietri
- Giovanna D'Elia
- Giuditta Benincasa
- Giuseppe Ferraro
- Gemma Caliendo
- Giovanni Francesco Nicoletti
- Claudio Napoli
-
Affiliations: Department of Precision Medicine, University of Campania ‘Luigi Vanvitelli’, I-80138 Naples, Italy, Unit of Clinical and Molecular Pathology, AOU, University of Campania ‘Luigi Vanvitelli’, I-80138 Naples, Italy, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania ‘Luigi Vanvitelli’, I-80138 Naples, Italy, Multidisciplinary Department of Medical, Surgical and Dental Sciences, Plastic Surgery Unit, University of Campania ‘Luigi Vanvitelli’, I-80138 Naples, Italy - Published online on: October 29, 2021 https://doi.org/10.3892/ijo.2021.5278
- Article Number: 98
This article is mentioned in:
Abstract
 |
 |
|
Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol. 28:1117–1123. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Salta S, P Nunes S, Fontes-Sousa M, Lopes P, Freitas M, Caldas M, Antunes L, Castro F, Antunes P, Palma de Sousa S, et al: A DNA methylation-based test for breast cancer detection in circulating cell-free DNA. J Clin Med. 7:4202018. View Article : Google Scholar : PubMed/NCBI | |
|
Oltra SS, Peña-Chilet M, Flower K, Martinez MT, Alonso E, Burgues O, Lluch A, Flanagan JM and Ribas G: Acceleration in the DNA methylation age in breast cancer tumours from very young women. Sci Rep. 9:149912019. View Article : Google Scholar : PubMed/NCBI | |
|
Schiano C, Soricelli A, De Nigris F and Napoli C: New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions. Expert Rev Clin Immunol. 15:289–301. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jeong S, Park MJ, Song W and Kim HS: Current immunoassay methods and their applications to clinically used biomarkers of breast cancer. Clin Biochem. 78:43–57. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Schiano C, Franzese M, Pane K, Garbino N, Soricelli A, Salvatore M, de Nigris F and Napoli C: Hybrid 18F-FDG-PET/MRI measurement of standardized uptake value coupled with yin yang 1 signature in metastatic breast cancer. a preliminary study. Cancers (Basel). 11:14442019. View Article : Google Scholar : PubMed/NCBI | |
|
Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES and Cardoso F: Male breast cancer: A disease distinct from female breast cancer. Breast Cancer Res Treat. 173:37–48. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Khan NAJ and Tirona M: An updated review of epidemiology, risk factors, and management of male breast cancer. Med Oncol. 38:392021. View Article : Google Scholar : PubMed/NCBI | |
|
Romagnolo DF, Daniels KD, Grunwald JT, Ramos SA, Propper CR and Selmin OI: Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds. Mol Nutr Food Res. 60:1310–1329. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Vietri MT, Molinari AM, Caliendo G, De Paola ML, Giovanna D, Gambardella AL, Petronella P and Cioffi M: Double heterozygosity in the BRCA1 and BRCA2 genes in Italian family. Clin Chem Lab Med. 51:2319–2324. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vietri MT, Caliendo G, Casamassimi A, Cioffi M, De Paola ML, Napoli C and Molinari AM: A novel PALB2 truncating mutation in an Italian family with male breast cancer. Oncol Rep. 33:1243–1247. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pasculli B, Barbano R and Parrella P: Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Semin Cancer Biol. 51:22–35. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sher G, Salman NA, Khan AQ, Prabhu KS, Raza A, Kulinski M, Dermime S, Haris M, Junejo K and Uddin S: Epigenetic and breast cancer therapy: promising diagnostic and therapeutic applications. Semin Cancer Biol. Aug 25–2020.(Epub ahead of print). doi: org/10.1016/j.semcancer.2020.08.009. View Article : Google Scholar : PubMed/NCBI | |
|
Bhat SA, Majid S, Wani HA and Rashid S: Diagnostic utility of epigenetics in breast cancer - A review. Cancer Treat Res Commun. 19:1001252019. View Article : Google Scholar : PubMed/NCBI | |
|
Park HL: Epigenetic biomarkers for environmental exposures and personalized breast cancer prevention. Int J Environ Res Public Health. 17:11812020. View Article : Google Scholar : PubMed/NCBI | |
|
Stewart CM and Tsui DWY: Circulating cell-free DNA for non-invasive cancer management. Cancer Genet. 228-229:169–179. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Colao A, de Nigris F, Modica R and Napoli C: Clinical epigenetics of neuroendocrine tumors: The road ahead. Front Endocrinol (Lausanne). 11:6043412020. View Article : Google Scholar : PubMed/NCBI | |
|
Schiano C, Casamassimi A, Rienzo M, de Nigris F, Sommese L and Napoli C: Involvement of mediator complex in malignancy. Biochim Biophys Acta. 1845:66–83. 2014.PubMed/NCBI | |
|
Sarno F, Benincasa G, List M, Barabasi AL, Baumbach J, Ciardiello F, Filetti S, Glass K, Loscalzo J, Marchese C, et al International Network Medicine Consortium, : Clinical epigenetics settings for cancer and cardiovascular diseases: Real-life applications of network medicine at the bedside. Clin Epigenetics. 13:662021. View Article : Google Scholar : PubMed/NCBI | |
|
Benincasa G, Franzese M, Schiano C, Marfella R, Miceli M, Infante T, Sardu C, Zanfardino M, Affinito O, Mansueto G, et al: DNA methylation profiling of CD04+/CD08+ T cells reveals pathogenic mechanisms in increasing hyperglycemia: PIRAMIDE pilot study. Ann Med Surg (Lond). 60:218–226. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Rodgers KM, Udesky JO, Rudel RA and Brody JG: Environmental chemicals and breast cancer: An updated review of epidemiological literature informed by biological mechanisms. Environ Res. 160:152–182. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Klutstein M, Nejman D, Greenfield R and Cedar H: DNA methylation in cancer and aging. Cancer Res. 76:3446–3450. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Murtha M and Esteller M: Extraordinary cancer epigenomics: Thinking outside the classical coding and promoter box. Trends Cancer. 2:572–584. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Brooks J, Cairns P and Zeleniuch-Jacquotte A: Promoter methylation and the detection of breast cancer. Cancer Causes Control. 20:1539–1550. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shargh SA, Sakizli M, Khalaj V, Movafagh A, Yazdi H, Hagigatjou E, Sayad A, Mansouri N, Mortazavi-Tabatabaei SA and Khorram Khorshid HR: Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol. 31:2502014. View Article : Google Scholar : PubMed/NCBI | |
|
Avraham A, Cho SS, Uhlmann R, Polak ML, Sandbank J, Karni T, Pappo I, Halperin R, Vaknin Z, Sella A, et al: Tissue specific DNA methylation in normal human breast epithelium and in breast cancer. PLoS One. 9:e918052014. View Article : Google Scholar : PubMed/NCBI | |
|
de Almeida BP, Apolónio JD, Binnie A and Castelo-Branco P: Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers. BMC Cancer. 19:2192019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Zhou L, Chen J, Su J, Shen W, Liu B, Zhou J, Yu S and Qian J: A four-gene signature for prognosis in breast cancer patients with hypermethylated IL15RA. Oncol Lett. 17:4245–4254. 2019.PubMed/NCBI | |
|
Mao Y, Fu A, Hoffman AE, Jacobs DI, Jin M, Chen K and Zhu Y: The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications. Tumour Biol. 36:3533–3539. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sasidharan Nair V, El Salhat H, Taha RZ, John A, Ali BR and Elkord E: DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin Epigenetics. 10:782018. View Article : Google Scholar : PubMed/NCBI | |
|
Cui X, Jing X, Wu X, Xu J, Liu Z, Huo K and Wang H: Analyses of DNA methylation involved in the activation of nuclear karyopherin alpha 2 leading to identify the progression and prognostic significance across human breast cancer. Cancer Manag Res. 12:6665–6677. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shukla S, Penta D, Mondal P and Meeran SM: Epigenetics of breast cancer: Clinical status of epi-drugs and phytochemicals. Adv Exp Med Biol. 1152:293–310. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, Weitzman SA, Korz D and Sukumar S: Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 61:921–925. 2001.PubMed/NCBI | |
|
Vermeulen MA, van Deurzen CHM, Doebar SC, de Leng WW, Martens JW, van Diest PJ and Moelans CB: Promoter hypermethylation in ductal carcinoma in situ of the male breast. Endocr Relat Cancer. 26:575–584. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tao C, Luo R, Song J, Zhang W and Ran L: A seven-DNA methylation signature as a novel prognostic biomarker in breast cancer. J Cell Biochem. 121:2385–2393. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Delgado-Cruzata L, Wu HC, Perrin M, Liao Y, Kappil MA, Ferris JS, Flom JD, Yazici H, Santella RM and Terry MB: Global DNA methylation levels in white blood cell DNA from sisters discordant for breast cancer from the New York site of the Breast Cancer Family Registry. Epigenetics. 7:868–874. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Z, Bolick SC, DeRoo LA, Weinberg CR, Sandler DP and Taylo JA: Epigenome-wide association study of breast cancer using prospectively collected sister study samples. J Natl Cancer Inst. 105:694–700. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kuchiba A, Iwasaki M, Ono H, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Tsugane S and Yoshida T: Global methylation levels in peripheral blood leukocyte DNA by LUMA and breast cancer: A case-control study in Japanese women. Br J Cancer. 110:2765–2771. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cho YH, McCullough LE, Gammon MD, Wu HC, Zhang YJ, Wang Q, Xu X, Teitelbaum SL, Neugut AI, Chen J, et al: Promoter hypermethylation in white blood cell DNA and breast cancer risk. J Cancer. 6:819–824. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Q, Cheng J, Cao X, Surowy H and Burwinkel B: Blood-based DNA methylation as biomarker for breast cancer: A systematic review. Clin Epigenetics. 8:1152016. View Article : Google Scholar : PubMed/NCBI | |
|
Boyne DJ, O'Sullivan DE, Olij BF, King WD, Friedenreich CM and Brenner DR: Physical activity, global DNA methylation, and breast cancer risk: A systematic literature review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 27:1320–1331. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Brennan K, Garcia-Closas M, Orr N, Fletcher O, Jones M, Ashworth A, Swerdlow A, Thorne H, Riboli E, Vineis P, et al KConFab Investigators, : Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res. 72:2304–2313. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ and Brenner H: Epigenotyping in peripheral blood cell DNA and breast cancer risk: A proof of principle study. PLoS One. 3:e26562008. View Article : Google Scholar : PubMed/NCBI | |
|
Shirkavand A, Boroujeni ZN and Aleyasin SA: Examination of methylation changes of VIM, CXCR4, DOK7, and SPDEF genes in peripheral blood DNA in breast cancer patients. Indian J Cancer. 55:366–371. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zmetakova I, Danihel L, Smolkova B, Mego M, Kajabova V, Krivulcik T, Rusnak I, Rychly B, Danis D, Repiska V, et al: Evaluation of protein expression and DNA methylation profiles detected by pyrosequencing in invasive breast cancer. Neoplasma. 60:635–646. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Benincasa G, Mansueto G and Napoli C: Fluid-based assays and precision medicine of cardiovascular diseases: The ‘hope’ for Pandora's box? J Clin Pathol. 72:785–799. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, et al: Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 158:1110–1122. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Sun L, Li C, Li X, Zhang Y, Yu Y and Xia W: Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients. Biomed Mater Eng. 26 (Suppl 1):S2217–S2222. 2015.PubMed/NCBI | |
|
Ahmed IA, Pusch CM, Hamed T, Rashad H, Idris A, El-Fadle AA and Blin N: Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Cancer Genet Cytogenet. 199:96–100. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R and Dahl E: Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 15:R42013. View Article : Google Scholar : PubMed/NCBI | |
|
Swellam M, Abdelmaksoud MDE, Sayed Mahmoud M, Ramadan A, Abdel-Moneem W and Hefny MM: Aberrant methylation of APC and RARβ2 genes in breast cancer patients. IUBMB Life. 67:61–68. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bao-Caamano A, Rodriguez-Casanova A and Diaz-Lagares A: Epigenetics of circulating tumor cells in breast cancer. Adv Exp Med Biol. 1220:117–134. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chimonidou M, Strati A, Malamos N, Kouneli S, Georgoulias V and Lianidou E: Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer. Oncotarget. 8:72054–72068. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dart A: Methylated clusters. Nat Rev Cancer. 19:1252019. View Article : Google Scholar : PubMed/NCBI | |
|
Zurita M, Lara PC, del Moral R, Torres B, Linares-Fernández JL, Arrabal SR, Martínez-Galán J, Oliver FJ and Ruiz de Almodóvar JM: Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer. 10:2172010. View Article : Google Scholar : PubMed/NCBI | |
|
Radpour R, Barekati Z, Kohler C, Lv Q, Bürki N, Diesch C, Bitzer J, Zheng H, Schmid S and Zhong XY: Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One. 6:e160802011. View Article : Google Scholar : PubMed/NCBI | |
|
Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, Georgoulias V and Lianidou E: CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin Biochem. 46:235–240. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pareja F and Reis-Filho JS: Triple-negative breast cancers - a panoply of cancer types. Nat Rev Clin Oncol. 15:347–348. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Okuma HS and Yonemori K: BRCA gene mutations and poly(ADP-Ribose) polymerase inhibitors in triple-negative breast cancer. Adv Exp Med Biol. 1026:271–286. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fackler MJ, Cho S, Cope L, Gabrielson E, Visvanathan K, Wilsbach K, Meir-Levi D, Lynch CF, Marks J, Geradts J, et al: DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. NPJ Breast Cancer. 6:32020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Zhang J and Dai X: DNA methylation profiles capturing breast cancer heterogeneity. BMC Genomics. 20:8232019. View Article : Google Scholar : PubMed/NCBI | |
|
Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Córdoba A, Azúa YR, Aguiar B, Beloqui R, Armendáriz P, Arriola M, Martín-Sánchez E, et al: ADAM12 is a potential therapeutic target regulated by hypomethylation in triple-negative breast cancer. Int J Mol Sci. 21:9032020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu X, Shan L, Wang F, Wang J, Wang F, Shen G, Liu X, Wang B, Yuan Y, Ying J, et al: Hypermethylation of BRCA1 gene: Implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer. Breast Cancer Res Treat. 150:479–486. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Good CR, Panjarian S, Kelly AD, Madzo J, Patel B, Jelinek J and Issa JJ: TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer. Cancer Res. 78:4126–4137. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Zheng X, Ren L, Fu W, Liu J, Xv J, Liu S, Wang J and Du G: Epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer. Ann Transl Med. 7:7232019. View Article : Google Scholar : PubMed/NCBI | |
|
van Hoesel AQ, Sato Y, Elashoff DA, Turner RR, Giuliano AE, Shamonki JM, Kuppen PJ, van de Velde CJ and Hoon DS: Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer. 108:2033–2038. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Laham-Karam N, Pinto GP, Poso A and Kokkonen P: Transcription and translation inhibitors in Cancer treatment. Front Chem. 8:2762020. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL and Morey L: Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 12:17862021. View Article : Google Scholar : PubMed/NCBI | |
|
Martínez-Galán J, Torres-Torres B, Núñez MI, López-Peñalver J, Del Moral R, Ruiz De Almodóvar JM, Menjón S, Concha A, Chamorro C, Ríos S, et al: ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer. 14:592014. View Article : Google Scholar : PubMed/NCBI | |
|
Palomeras S, Diaz-Lagares Á, Viñas G, Setien F, Ferreira HJ, Oliveras G, Crujeiras AB, Hernández A, Lum DH, Welm AL, et al: Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer. Breast Cancer Res. 21:792019. View Article : Google Scholar : PubMed/NCBI | |
|
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, et al: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. PLoS One. 15:e02380212020. View Article : Google Scholar : PubMed/NCBI | |
|
Hamadneh L, Abu-Irmaileh B, Al-Majawleh M, Bustanji Y, Jarrar Y and Al-Qirim T: Doxorubicin-paclitaxel sequential treatment: Insights of DNA methylation and gene expression changes of luminal A and triple negative breast cancer cell lines. Mol Cell Biochem. 476:3647–3654. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
de Nigris F, Ruosi C and Napoli C: Clinical efficiency of epigenetic drugs therapy in bone malignancies. Bone. 143:1156052021. View Article : Google Scholar : PubMed/NCBI | |
|
Buocikova V, Rios-Mondragon I, Pilalis E, Chatziioannou A, Miklikova S, Mego M, Pajuste K, Rucins M, Yamani NE, Longhin EM, et al: Epigenetics in breast cancer therapy-new strategies and future nanomedicine perspectives. Cancers (Basel). 12:36222020. View Article : Google Scholar : PubMed/NCBI | |
|
Schröder R, Illert AL, Erbes T, Flotho C, Lübbert M and Duque-Afonso J: The epigenetics of breast cancer - Opportunities for diagnostics, risk stratification and therapy. Epigenetics. 23:1–13. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Griffiths EA and Gore SD: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 45:23–30. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, et al: Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat: A phase ii national cancer institute/stand up to cancer study. Clin Cancer Res. 23:2691–2701. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Gun M and Hong XY: Induced tamoxifen resistance is mediated by increased methylation of e-cadherin in estrogen receptor-expressing breast cancer cells. Sci Rep. 9:141402019. View Article : Google Scholar : PubMed/NCBI | |
|
Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, Bellani M, Zou Y, Singh ZN, Duong VH, et al: Enhancing the cytotoxic effects of PARP inhibitors with DNA demethy lating agents - a potential therapy for cancer. Cancer Cell. 30:637–650. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
McLaughlin LJ, Stojanovic L, Kogan AA, Rutherford JL, Choi EY, Yen RC, Xia L, Zou Y, Lapidus RG, Baylin SB, et al: Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency. Proc Natl Acad Sci USA. 117:17785–17795. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Selvakumar P, Badgeley A, Murphy P, Anwar H, Sharma U, Lawrence K and Lakshmikuttyamma A: Flavonoids and other polyphenols act as epigenetic modifiers in breast cancer. Nutrients. 12:7612020. View Article : Google Scholar : PubMed/NCBI | |
|
Su Y, Hopfinger NR, Nguyen TD, Pogash TJ, Santucci-Pereira J and Russo J: Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. J Exp Clin Cancer Res. 37:3142018. View Article : Google Scholar : PubMed/NCBI | |
|
Scognamiglio G, De Chiara A, Parafioriti A, Armiraglio E, Fazioli F, Gallo M, Aversa L, Camerlingo R, Cacciatore F, Colella G, et al: Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. Br J Cancer. 121:979–982. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Terracciano D, Terreri S, de Nigris F, Costa V, Calin GA and Cimmino A: The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer. Biochim Biophys Acta Rev Cancer. 1868:449–455. 2017. View Article : Google Scholar : PubMed/NCBI |
